Cardiol Therapeutics Inc Class A (TO:CRDL) — Market Cap & Net Worth
Market Cap & Net Worth: Cardiol Therapeutics Inc Class A (CRDL)
Cardiol Therapeutics Inc Class A (TO:CRDL) has a market capitalization of $148.65 Million (CA$205.49 Million) as of May 2, 2026. Listed on the TO stock exchange, this Canada-based company holds position #17675 globally and #569 in its home market, demonstrating a -1.08% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cardiol Therapeutics Inc Class A's stock price CA$1.84 by its total outstanding shares 111680087 (111.68 Million). Analyse Cardiol Therapeutics Inc Class A operating cash flow efficiency to see how efficiently the company converts income to cash.
Cardiol Therapeutics Inc Class A Market Cap History: 2018 to 2026
Cardiol Therapeutics Inc Class A's market capitalization history from 2018 to 2026. Data shows change from $359.51 Million to $148.65 Million (-10.45% CAGR).
Cardiol Therapeutics Inc Class A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cardiol Therapeutics Inc Class A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2389.99x
Cardiol Therapeutics Inc Class A's market cap is 2389.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $224.59 Million | $78.76K | -$20.65 Million | 2851.57x | N/A |
| 2021 | $188.24 Million | $78.76K | -$24.72 Million | 2389.99x | N/A |
Competitor Companies of CRDL by Market Capitalization
Companies near Cardiol Therapeutics Inc Class A in the global market cap rankings as of May 2, 2026.
Key companies related to Cardiol Therapeutics Inc Class A by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Cardiol Therapeutics Inc Class A Historical Marketcap From 2018 to 2026
Between 2018 and today, Cardiol Therapeutics Inc Class A's market cap moved from $359.51 Million to $ 148.65 Million, with a yearly change of -10.45%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$148.65 Million | +40.46% |
| 2025 | CA$105.83 Million | -29.19% |
| 2024 | CA$149.46 Million | +68.18% |
| 2023 | CA$88.87 Million | +59.42% |
| 2022 | CA$55.74 Million | -70.39% |
| 2021 | CA$188.24 Million | -16.19% |
| 2020 | CA$224.59 Million | -39.30% |
| 2019 | CA$370.01 Million | +2.92% |
| 2018 | CA$359.51 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Cardiol Therapeutics Inc Class A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $148.65 Million USD |
| MoneyControl | $148.65 Million USD |
| MarketWatch | $148.65 Million USD |
| marketcap.company | $148.65 Million USD |
| Reuters | $148.65 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cardiol Therapeutics Inc Class A
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for … Read more